To compare the ability of activated charcoal dressings with that of a hydrocolloid dressing to reduce the wound area of chronic wounds.
This process makes charcoal extremely porous. As a consequence, activated carbon has a large pore volume and a large surface area, giving it a unique adsorption capacity.
2 When applied onto a wound, activated charcoal dressings adsorb bacteria, locally released toxins and wound degradation products, thereby promoting wound healing. 3 The fi rst available dressing of this type was Actisorb (Systagenix Wound Management). Later, silver was added to the charcoal cloth (Actisorb Silver 220) as silver ions have a broad-spectrum antimicrobial effect, 4,5 and so should help kill adsorbed bacteria within the carbon matrix. It is possible that this might help promote healing in stagnating chronic wounds, which have a high bioburden. [6] [7] [8] Two randomised controlled trials, briefl y reported in 2003 in Journal des Plaies et Cicatrisations, investigated the healing outcomes achieved with Actisorb. 9 Both had similar study designs (open, four-week, parallel group), with one following the use of Actisorb (without silver) on pressure ulcers (PUs) and the other the use of Actisorb Silver 220 on venous leg ulcers (VLUs). Both used a carboxymethylcellulose dressing (hydrocolloid) as the control. This paper describes the methodology and results of the two studies.
The two studies are described separately below. Both studies were approved by the same ethics committee (Comité Consultatif de Protection des Personnes dans la Recherche Biomédiale) at the Hôtel-Dieu University Hospital, Paris, France. All subjects received detailed information about the study protocols and gave written informed consent to participate.
Method: pressure ulcer study
Six hospitals participated in the PU study. Both inpatients and outpatients were eligible for recruitment into the study.
Inclusion criteria were: PUs with an area ranging from 5 to 100cm 2 PUs of less than three months' duration PUs graded IIc or IV on the Yarkoni classifi cation 10 -that is, full-thickness ulcers that had not extended down to the bone. This classifi cation system was used throughout the study hospitals to grade PUs, and so was incorporated into the study design. 
Randomisation
Patients were randomly allocated to either the test dressing (Actisorb) or the control (DuoDerm, ConvaTec). Randomisation was by blocks of four: identical sealed boxes containing the allocated dressings, gauze and saline were randomly allocated to each patient. The box reference number indicated which study arm the patient had been allocated to, although this was unknown to the patient and investigator. The box reference numbers were verifi ed by a coordinating centre before allocation.
Intervention
Standardised PU management strategies (regular repositioning and use of pressure-redistributing surfaces) were applied to all patients.
Necrotic tissue and debris were sharp debrided. The wounds were cleansed with sterile saline only, and either the test dressing or the control dressing was then applied. In the case of large wounds, two dressings could be applied side by side. Dressings were impregnated with saline, covered with gauze and secured with a non-compressive bandage. The study protocol stipulated that the dressing should be changed two to three times per week or more frequently in cases of abundant exudation.
The test dressing was applied for four weeks. After four weeks, patients in the treatment group whose ulcers had not healed switched from the test dressing to Adaptic (Systagenix Wound Management). Only results for the fi rst four weeks, when the test dressing was used, are given here. No secondary dressing was used at any stage in the study.
Assessment
The investigators assessed the patients/wounds once weekly for four weeks, or less if complete wound closure (defi ned as complete re-epithelialisation) occurred before then.
At each weekly assessment, the wound was traced and photographed, and the exudate level and wound bed characteristics were assessed. Box 1 gives details on the assessment of the wound bed characteristics, which included assessment of the extent of devitalised tissue.
All wound tracings were measured by two independent, experienced clinicians who were unaware of the treatment allocation. Each evaluator twice measured the largest and shortest wound dimensions, and the mean of the two wound axis measurements was used as the fi nal value. Estimation of the wound surface area was based on the sum of the two axes.
All local care was performed and recorded by the same nursing team in each of the participating centres.
Method: leg ulcer ulcer study
Seven hospitals particpated in this study. Two also participated in the PU study.
Inclusion criteria were: Ulcers of primarily venous origin (ankle brachial pressure index >0.7) that were not contraindicated to compression bandaging VLUs of <12 months' duration VLUs with an area ranging from 5 to 100cm 2 VLUs considered by the investigators to have abundant necrotic tissue and slough (covering >50% of the wound surface).
Exclusion criteria were: Poorly controlled diabetes (in the investigator's opinion)
Presence of peri-wound eczema Severe illness Infected ulcers requiring systemic antibiotics
Box 1. Secondary outcome: percentage of completely debrided wound
Actisorb was used in conjunction with sharp debridement to remove the necrotic tissue. One of the secondary outcomes assessed was the percentage of completely debrided tissue -that is, no exudation, no necrotic tissue and <25% of the wound surface covered with slough (a score of 0 on the scale outlined below).
A colormetric scale was used to record the percentage of wound surface covered with necrotic tissue (black), slough (yellow), granulation (red) and reepithelialisation (pink) tissue. The following were scored at each assessment, according to the scale developed for these two studies: Exudation: 0 = none; 1 = mild to moderate; 2 = abundant Slough: 0 = <25% of wound area covered with slough; 1 = 25-50% covered; 2 = >50% covered Necrotic tissue: 0 = none; 1 = <25% of wound area covered; 2 = 25-50% covered; 3 = >50% covered
The total score could range from 0 to 7. A score of 0 was considered to indicate appropriate debridement. Baseline wound characteristics are given in Tables 1  and 2 .
At the end of the four weeks, 11 (37.9%) PUs treated with the test dressing were totally debrided, compared with fi ve (16.1%) control-treated PUs (p=0.056); 18 VLUs (60%) treated with the test dressing were totally debrided compared with 17 (56.7%) controls. While these results are of interest, it should be noted that they are attributable to the use of sharp debridement as well as the dressing Known allergy to the study dressing Previous use of the test dressing. One ulcer per patient was included in the study.
Randomisation
The same randomisation procedure was used as in the PU study, except that the study dressing was Actisorb Silver 220 and the box also contained compression bandaging.
Intervention
Again, the same protocol was used as for the PU study, except that patients were strongly recommended to wear compression bandage on a daily basis. All patients used the same system: Bifl ex 16, Thuasne, France. Overall, the investigators considered patient concordance with compression throughout the study to be acceptable in 12 (40%) and 15 (50%) of the patients in the test and control groups respectively.
Assessment
VLUs were assessed using the same protocol as for the PU study
Study outcomes
The primary study outcome for both studies was the absolute reduction in wound area (cm 2 ) achieved in the fi rst four weeks of the study, when the test dressing was applied, compared with baseline.
The secondary outcome measure for both studies was the relative (percentage) reduction in wound area compared with baseline. Another secondary outcome measure was the percentage reduction of debrided tissue. Assessment methods and results for this are given in Box 1.
Statistical analysis
No a priori power calculations were performed. Sample sizes were pragmatically determined with the view that 30 patients per group would be suffi cient to detect clinically relevant trends in favour of the test dressing.
All analyses used data from the intention-to-treat population (defi ned as all randomised patients whose wounds were traced in at least one assessment during the fi rst four weeks of the study).
Scale variables are presented as mean ± standard deviation or as median (range).
Absolute and relative changes in wound area were compared between groups at weeks 1, 2, 3 and 4 using the non-parametric Mann-Whitney U test. No adaptation of the alpha risk for repeated testing was used. Ordinal and nominal variables were compared using either the chi-square test or Fisher's exact test. SPS software was used. A p value of less than 5% (<0.05) was considered as indicating statistical signifi cance.
Results: pressure ulcer study
Patient and wound characteristics
Sixty patients were recruited into the PU study: 29 to the treatment group and 31 to the control group. One patient was not included in the intention-totreat analysis because her wound tracing was not available for analysis (she died suddenly two days after randomisation). Patients and wound characteristics are presented in Table 1 .
In 42 cases (71.2%), the study PU was located on the heel. For the sample as a whole, 29 patients (49.2%) were able to ambulate with or without help, 21 (35.6%) had very limited mobility and nine (15.3%) were bedridden. None of the patients had Baseline characteristics (including wound characteristics) were comparable between groups.
Withdrawals
Fourteen patients (23.7%) withdrew from this study. Seven withdrew from the treatment group for the following reasons:
Wound stagnation (n=3) Intercurrent event (septicaemia) (n=1) Other reasons (one death, returned home in two cases) (n=3) Seven patients also withdrew from the control group:
Local adverse event (wound infection) (n=1) Wound stagnation (n=2) Intercurrent events (hip fracture and death) (n=2) Wound graft (n=1) Other reasons (wish to return home) (n=1)
Reduction in wound area
The median reductions in wound area (cm 2 ), compared with baseline, reported for both groups at weeks 1-4 are given in Table 2 . At week 1, the median reduction in wound area was -2.5cm 2 and 0.0cm 2 in the treatment and control groups respectively. This was not statistically signifi cant (p=0.255). While a larger median reduction was reported for the treatment group throughout the study period, this does not reach statistical signifi cance.
Percentage reduction
The median percentage reductions in wound size, compared with baseline, reported for both groups at weeks 1-4 are given in Table 3 . Again, wound regression was higher at week 1 in the test group but the difference in favour of the test dressing was not statistically signifi cant different (-11.7% versus 0.0). This difference was not maintained throughout the study, with a median reduction of -26.9% reported for the treatment group compared with -18.5% for the control group at week 4.
Dressing tolerability
Local adverse events reported by investigators are presented in Table 4 . Two patients in the treatment group reported adverse events (6.9%) compared with seven in the control group (161.1%).
Results: venous leg ulcer study
Patient and wound characteristics
Sixty patients were recruited into the VLU study, 30 to the test dressing group and 30 to the control group. Patient and wound characteristics are given in Table 5 .
Of the patients recruited to the VLU study, eight (13.8%) had diabetes. For the group as a whole, 16 (26.7%) had a history of venous thrombosis, and 27 (45%) were already being treated with compression at inclusion. Sixteen (53.3%) and 19 (63.3%) patients given the test and control dressing respectively had a history of ulceration. Baseline characteristics (including wound characteristics) were comparable between groups.
Withdrawals
Seven patients (11.7%) withdrew from the VLU study. Only one patient withdrew from the test dressing (hospitalisation for heart failure). Six patients withdrew from the control group for the following reasons:
Local adverse event (eczema) (n=2) Intercurrent event (death) (n=1) Other reasons: withdrawal of consent (n=2) and discharge home (n=1)
Reduction in wound area
The median reductions in wound area (cm 2 ), compared with baseline, reported for both groups at weeks 1-4 are given in Table 6 . At week 1, the median reduction was -2.2cm 2 and -0.1cm 2 for the treatment and control groups respectively (p=0.066) and reached -4.5cm 2 and -3.5cm 2 respectively at week 4.
Percentage reduction
The median percentage reductions in wound size, compared with baseline, reported for both groups at weeks 1-4 are given in Table 7 . At week 1, median reductions reported were -16.4% and -0.9% for the treatment and control groups respectively (p=0.074). By week 4, the percentage reductions reported were similar for the both groups: -35.6% versus -40.9%.
Dressing tolerability
Local adverse events reported by the investigators are presented in Table 8 . Five patients reported adverse events in the treatment group (13.3%), compared with 20 in the control group (33.3%).
Discussion
These results support those of other studies performed on Actisorb. In Mulligan et al.'s RCT, 101 subjects with ulcers were treated with either Actisorb (without silver) or a control (any other dressing regarded as most appropriate by investigators) for six weeks, unless healing occurred sooner.
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Compared with baseline, the mean percentage reduction in wound area was statistically signifi cant for the treatment group (28.7% ± 3.9%) versus the control (11.7% ± 6.8%). In addition, the test dressing was found to be statistically superior in terms of reducing exudate levels, malodour and oedema (p=0.005). Wunderlich et al., in their RCT, randomised 40 patients with chronic VLUs to receive treatment with either Actisorb Silver 220 or zinc paste for six weeks. Results showed that use of the test dressing resulted in a statistically signifi cant reduction in wound area when compared with the controls (p<0.05), with 6/19 evaluated patients in the treatment group healing fully versus 2/19 evaluated patients in the control group.
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Evidence from non-controlled studies, large population surveys and case studies also support the clinical benefi t of using Actisorb dressing in various clinical situations. 9, 13 Furthermore, in the present study, patients in the treatment group reported fewer dressing-related adverse events. The most frequent adverse event reported in the control groups was maceration/high exudate level, but this was not reported in either of the two treatment groups. This suggests that, by binding toxins, Actisorb helps to promote healing.
Activated charcoal has been reported to remove endo-and exotoxins from fl uid in vitro.
14 Other in vitro studies have found that, when submerged in a milieu enriched with Escherichia coli, activated charcoal removed 90-95% of this toxin. 15, 16 In in vitro and in vivo experiments using a murine model of gut-derived endotoxemia, activated charcoal was able to bind enotoxin in both test methods. 17 It also has been shown that activated charcoal can adsorb bacteria, viruses and various other biochemicals in vitro and in vivo. 18, 19 Additionally, ex vivo and in vitro, activated charcoal fi lters has been found to fi lter infl ammatory chemokines and cytokines such as IL-8 or TNF-α from blood. [20] [21] [22] When silver is incorporated in the activated charcoal matrix, it is not released. However, an in vitro study found that the silver killed the bacteria adsorbed by the activate charcoal, suggesting that it will reduce the bioburden. 23 Verdu Soriano et al. clearly confi rmed that Actisorb Silver 220 substantially reduced bacterial burden. 24 
Study limitations
While following the same methodology, including blind evaluation of wound tracings, these studies had small sample size, so were underpowered. Nevertheless, it is of interest that both indicated that the test dressing may help to promote healing, regardless of the wound aetiology.
Conclusion
Experimental and clinical data indicate the potential usefulness of using activated charcoal impregnated with silver in the management of chronic wounds, even at the debridement stage. This type of dressing may help remove from the wound bed fl uid and toxins that impair the healing process. Bleeding at dressing removal 0 1
